High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

Inclusion Criteria: * Patients diagnosed with schizophrenia or schizoaffective disorder * Able to give written informed consent. * Moderate psychosis persists although compliant with medication * Patients must have an inadequate response to two antipsychotic medications (can be risperidone, oral or long acting - but not required), at doses that are within the upper end of the standard dosage range * Patients must have a Clinical Global Impression - Severity (CGI-S) scale score at screening of at least moderate severity and a Personal and Social Performance Scale (PSP) score of 60 or below. * At the time of screening, eligible patients will be receiving or have received treatment with risperidone oral or Consta, or a combination that does not exceed 50 mg q 2 weeks of Consta or oral risperidone 8 mg/day for at least 6 weeks within seven years of study entry without satisfactory response as documented in the medical record Risperidone * Patients who have received Consta injectable medication within the specified dose range for no more than a month prior to the onset of the study will be eligible. Patients receiving mood stabilizers or antidepressants, or both, in addition to risperidone oral or Consta, will be eligible * Patients may initially be inpatients or outpatients * Females of childbearing potential will be admitted only if they are on stable birth control medication and understand that they should not get pregnant during the course of the study. * All patients must ha…